1. Home
  2. VRTX vs ADI Comparison

VRTX vs ADI Comparison

Compare VRTX & ADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • ADI
  • Stock Information
  • Founded
  • VRTX 1989
  • ADI 1965
  • Country
  • VRTX United States
  • ADI United States
  • Employees
  • VRTX N/A
  • ADI N/A
  • Industry
  • VRTX EDP Services
  • ADI Semiconductors
  • Sector
  • VRTX Technology
  • ADI Technology
  • Exchange
  • VRTX Nasdaq
  • ADI Nasdaq
  • Market Cap
  • VRTX 104.8B
  • ADI 114.1B
  • IPO Year
  • VRTX 1991
  • ADI 1972
  • Fundamental
  • Price
  • VRTX $484.74
  • ADI $199.18
  • Analyst Decision
  • VRTX Buy
  • ADI Buy
  • Analyst Count
  • VRTX 25
  • ADI 23
  • Target Price
  • VRTX $508.09
  • ADI $253.59
  • AVG Volume (30 Days)
  • VRTX 1.4M
  • ADI 3.4M
  • Earning Date
  • VRTX 05-05-2025
  • ADI 05-21-2025
  • Dividend Yield
  • VRTX N/A
  • ADI 1.99%
  • EPS Growth
  • VRTX N/A
  • ADI N/A
  • EPS
  • VRTX N/A
  • ADI 3.13
  • Revenue
  • VRTX $11,020,100,000.00
  • ADI $9,337,627,000.00
  • Revenue This Year
  • VRTX $10.65
  • ADI $10.56
  • Revenue Next Year
  • VRTX $9.02
  • ADI $12.97
  • P/E Ratio
  • VRTX N/A
  • ADI $63.64
  • Revenue Growth
  • VRTX 11.66
  • ADI N/A
  • 52 Week Low
  • VRTX $377.85
  • ADI $182.57
  • 52 Week High
  • VRTX $519.88
  • ADI $247.10
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 44.78
  • ADI 36.58
  • Support Level
  • VRTX $471.50
  • ADI $201.28
  • Resistance Level
  • VRTX $513.98
  • ADI $214.90
  • Average True Range (ATR)
  • VRTX 12.35
  • ADI 4.83
  • MACD
  • VRTX -4.12
  • ADI -1.04
  • Stochastic Oscillator
  • VRTX 27.48
  • ADI 20.52

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About ADI Analog Devices Inc.

Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.

Share on Social Networks: